HIV

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events.

Lenacapavir works to both treat and prevent HIV, making it a promising drug should it be approved by the FDA later this month.

Exploring caregiver dependence and social determinants of health reveals critical barriers to HIV care for children, impacting treatment adherence and access, explains Priscilla Tsondai, MD, MPH.

People living with HIV who have taken highly active antiretroviral therapy can have hyperlipidemia predicted in advance by machine learning.

A panelist discusses how HIV treatment has evolved with tremendous improvements in efficacy, tolerability, and convenience, with exciting developments at the Conference on Retroviruses and Opportunistic Infections 2025, including new long-acting therapies for treatment and prevention that could last up to 2 years.

Sleep disorders and mental health complications were more common in adolescents or young adults who had HIV across the globe.

A panelist discusses how CD4 counts serve as measures of immune system status that typically increase by about 200 in the first year of antiretroviral therapy. Although there can be laboratory variability, these counts remain important for patient monitoring and identifying those at risk for complications.

The CDC uses molecular cluster detection to find the transmission of HIV that could pinpoint where there are gaps in HIV care.

Patients with HIV can take both their antiretroviral therapy (ART) and treatment to prevent tuberculosis safely to prevent infection and further spread of the virus.

The ability to estimate their last viral load was high among women with HIV living in British Columbia, even in those with adverse sociodemographic factors.

These guidelines act as an update to the 2016 guidelines for the use of nonoccupational postexposure prophylaxis (PEP) after exposure to HIV.

Viral suppression in HIV was more likely to be reported in women in Canada who had adherence to their antiretroviral therapy (ART) of 90% or higher.

Correlation to social drivers of health (SDOH) had an important correlation with polysubstance use.

Improving adherence to antiretroviral therapy (ART) in youth living with HIV requires interventions that target both family dynamics and any underlying mental illness.

Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.

Women living with HIV in Canada were found to have worse wellbeing when they had adversities related to social determinants of health (SDOH).

Countries located in sub-Saharan Africa would be most affected by all funding cuts to the international HIV response.

In part 1 of this interview with Katrina Ortblad, ScD, MPH, she addressed bridging gaps in HIV care with pharmacy-based solutions.

The Trump administration has expressed interest in eliminating or changing the Division of HIV Prevention in the CDC, which could introduce gaps in addressing the HIV epidemic.

The HIV prevention division could be rolled into another department of the HHS as soon as the end of the week.

Annie Antar, MD, PhD, discusses how patients with HIV can have different and longer-lasting symptoms of COVID-19.

Annie Antar, MD, PhD, discusses the association between the symptoms of long COVID and HIV status.

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.

When patients switched to either fostemsavir or the combination of dolutegravir/lamivudine (DTG/3TC), suppression was maintained in most patients.